Creabilis hires chief medical officer

Dr David Roblin joins the firm after holding leading roles at Pfizer and Bayer

Creabilis, a clinical stage European biotechnology company focused on dermatology, inflammation and pain, has appointed David Roblin as chief medical officer.

Roblin has gained extensive experience in the pharmaceutical industry in a career spanning more than 15 years. He has held leadership roles at Pfizer and Bayer across a range of therapy areas in research, development and commercial roles.

At Pfizer, Roblin was most recently senior vice president, head of research and site head for European r&d. Before this, he was head of anti-infectives at Bayer Medical Affairs.

In addition Roblin has chaired the research director’s group of the European Federation of Pharmaceutical Industries and Associations (EFPIA), and was a co-founder of the Innovative Medicines Initiative, a US$2bn public-private partnership with the European Commission.

You may also like